Navigation Links
Mount Sinai receives $3.4 million for largest study of personalized medicine in the clinical setting

Mount Sinai School of Medicine has been awarded a $3.4 million grant over four years from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) to begin the largest study of its kind, in which a patient's genomic risk for disease is revealed in a lab, and then entered into an electronic medical record for use in determining treatment in the clinical care setting.

Using DNA and plasma samples provided by patients, Mount Sinai researchers from the Charles R. Bronfman Institute for Personalized Medicine (IPM) will identify genetic markers of disease for each patient enrolled in the study and input them into Mount Sinai's new electronic medical records system in a safe and secure way. Physicians who are treating these patients in the clinical setting may then electronically access this genomic information and determine susceptibility for heart disease, responsiveness to certain medications, and a personalized course of treatment.

"Discovering genetic disease risk markers of major diseases such as heart disease through genome-wide genotyping was a major advance toward personalized medicine, but thus far the genomic information of individual patients has been limited to the laboratory and research setting," said Erwin Bottinger, MD, Director of the Charles R. Bronfman Institute for Personalized Medicine, and the Irene and Dr. Arthur M. Fishberg Professor of Medicine at Mount Sinai School of Medicine. "This will allow us for the first time to bring that critical individual genetic-disease risk information to the patient setting, which we believe will eventually have a tremendous impact on the practice of medicine."

The study, called the "Biorepository for Genomic Medicine in Diverse Communities," is part of a consortium of seven leading genomic medicine institutions called Electronic Medical Records and Genomics (eMERGE). As a member of the consortium, the IPM team hopes to have enrolled up to 20,000 patients from the Mount Sinai Biobank, which consists of consented patients representing the diverse communities surrounding The Mount Sinai Medical Center.

"This grant is a significant achievement for Mount Sinai, propelling us to the forefront of personalized medicine and its application in the clinical setting," said Dennis. S. Charney, MD, Anne and Joel Ehrenkranz Dean of Mount Sinai School of Medicine and Executive Vice President for Academic Affairs of The Mount Sinai Medical Center. "The future of medicine lies in genomics research and translating it into a patient-care setting. Mount Sinai's commitment to translational research makes us uniquely poised to lead that revolution."

Mount Sinai Biobank patients have provided DNA and plasma samples to aid in genomic and personalized medicine research, allowing Dr. Bottinger's team to validate and customize 288 previously-reported single nucleotide polymorphisms (SNPs) as genetic risk markers of major diseases, including heart, kidney, and liver disease, for Mount Sinai's racially and ethnically diverse patient populations. The IPM team is committed to ensuring that this information is made available in culturally appropriate, easy to understand formats, and will have the potential to benefit all patients.

The IPM research team will create a Biobank database that will have each of these individual's genetic-disease risk profiles for heart, kidney, and liver disease, as well as their likely response to different medications and potential side effects data that will be entered into Mount Sinai's electronic medical record system for patients who consent to participate in this new study.

The study will include one group of physicians and patients that will be randomized to a genomic-risk assessment, and another that will be randomized to a traditional risk assessment, using risk factors like cholesterol and high blood pressure when determining a patient's risk for heart disease. The team will evaluate whether the genomic-risk assessment, based on the presence of certain SNP genotypes as well as traditional risk factors, will lead to improved management of risk factors for heart disease in each patient and help prevent the onset of heart disease, as compared to the using traditional risk factors alone.

"The study will give the physicians in the genomic-risk assessment group access to each individual patient's genomic risk scores and predictors for treatment response and adverse drug reactions, allowing them to specifically tailor the patient's treatment and disease management," said Dr. Bottinger. "In addition, it gives them a rationale to treat high cholesterol and high blood pressure more aggressively to prevent them from causing or contributing to cardiovascular disease."

Additionally, the research team will also enter 3,000 Biobank patients into a pool of 32,000 patients as part of Genome-Wide Association Studies (GWAS) that will be conducted by the eMERGE consortium. The consortium hopes to identify genetic variants associated with 40 additional disease characteristics and symptoms, ideally making these genetic m available to treating physicians and allowing them to personalize their patients' treatments.


Contact: Mount Sinai Press Office
The Mount Sinai Hospital / Mount Sinai School of Medicine

Related biology news :

1. Guam researcher studies Mount Pinatubo ecosystem recovery
2. Pearl-flowered legume a surprise new find in the Cape Snowy Mountains, South Africa
3. Mount Sinai researchers develop new gene therapy for heart failure
4. Large numbers of birth defects seen near mountaintop mining operations
5. Mountain pine beetle activity may impact snow accumulation and melt, says CU-Boulder study
6. Mountain pine beetle marching east from Alberta
7. Human virus linked to deaths of endangered mountain gorillas
8. UCLA researchers engineer E. coli to produce record-setting amounts of alternative fuel
9. Recipe for family mealtimes calls for 3 ingredients in the right amounts
10. Islands in the sky: How isolated are mountain top plant populations?
11. New method will triple amount of genetic information from newborn blood spot screenings
Post Your Comments:
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology: